{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INX-08189",
    "query": {
      "intervention": "INX-08189"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T13:28:38.570Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01425970",
      "title": "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 210,
      "start_date": "2012-05",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • La Jolla, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01425970"
    },
    {
      "nct_id": "NCT01250366",
      "title": "Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HCV (Genotype 1)"
      ],
      "interventions": [
        {
          "name": "INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2010-10",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-07-12",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Plymouth, Minnesota • San Antonio, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250366"
    },
    {
      "nct_id": "NCT01732848",
      "title": "A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "BMS-986094/INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching BMS-986094/INX-08189",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2012-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-08-15",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Saint Paul, Minnesota • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01732848"
    },
    {
      "nct_id": "NCT01471717",
      "title": "Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "INX-08189 50 mg QD X 5 days",
          "type": "DRUG"
        },
        {
          "name": "INX-08189 / Victrelis 800 mg TID X three days",
          "type": "DRUG"
        },
        {
          "name": "Victrelis 800 mg TID x 3 days",
          "type": "DRUG"
        },
        {
          "name": "Victrelis 800 mg TID with INX-08189 50 mg QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo with Victrelis 800 mg",
          "type": "DRUG"
        },
        {
          "name": "Cohort 2: Victrelis 800 mg with Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-10",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2012-06-22",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01471717"
    },
    {
      "nct_id": "NCT01445795",
      "title": "Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "200 mg INX-08189 Fasted",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD Fasted",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo QD",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 with low-fat meal",
          "type": "DRUG"
        },
        {
          "name": "Placebo with low-fat meal",
          "type": "DRUG"
        },
        {
          "name": "100 mg INX-08189 BID Fasted",
          "type": "DRUG"
        },
        {
          "name": "Placebo BID Fasted",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-09",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-27",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445795"
    },
    {
      "nct_id": "NCT01629732",
      "title": "Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "BMS-986094",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-986094",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2013-03",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01629732"
    },
    {
      "nct_id": "NCT01846494",
      "title": "Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 113,
      "start_date": "2013-05-10",
      "completion_date": "2018-03-19",
      "has_results": true,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 12,
      "location_summary": "Anaheim, California • San Diego, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846494"
    },
    {
      "nct_id": "NCT01471704",
      "title": "Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "INX-08189 50 mg",
          "type": "DRUG"
        },
        {
          "name": "240 mg verapamil HCL ER",
          "type": "DRUG"
        },
        {
          "name": "50 mg dose of INX-08189 and 240 mg verapamil HCL ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-10",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2012-06-22",
      "last_synced_at": "2026-09-02T13:28:38.570Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01471704"
    }
  ]
}